Intermittent Schedules of the Oral RAF–MEK Inhibitor CH5126766/VS-6766 in Patients With RAS/RAF-Mutant Solid Tumors and Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Intermittent Schedules of the Oral RAF–MEK Inhibitor CH5126766/VS-6766 in Patients With RAS/RAF-Mutant Solid Tumours and Multiple Myeloma: A Single-Centre, Open-Label, Phase 1 Dose-Escalation and Basket Dose-Expansion Study
Lancet Oncol 2020 Nov 01;21(11)1478-1488, C Guo, M Chénard-Poirier, D Roda, M de Miguel, SJ Harris, IM Candilejo, P Sriskandarajah, W Xu, M Scaranti, A Constantinidou, J King, M Parmar, AJ Turner, S Carreira, R Riisnaes, L Finneran, E Hall, Y Ishikawa, K Nakai, N Tunariu, B Basu, M Kaiser, JS Lopez, A Minchom, JS de Bono, U BanerjiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.